Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Drug Farm reports DF-003 reduced kidney fibrosis in preclinical research, revealing a potential ALPK1 treatment pathway. Human efficacy remains unproven.
Pharma & Biotech
Pharma & Biotech
Drug Farm’s DF-003 shows early signal in ROSAH syndrome, but can ALPK1 inhibition hold up in pivotal testing?
Drug Farm’s DF-003 showed early Phase 1b benefit in ROSAH syndrome. Read what the ALPK1 data could change next.
Pharma & Biotech
Can Drug Farm turn ALPK1 inhibition into the first real disease-modifying approach for ROSAH syndrome?
Drug Farm won FDA orphan drug designation for DF-003 in ROSAH syndrome. Read what this rare disease milestone could change next.